Latest:
What Can We Learn From "Extreme Survivors" of Breast Cancer?
Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Mark Emberton, MD
Latest:
Dr. Emberton on Focal Therapy Techniques in Prostate Cancer
Mark Emberton, MD, professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London Hospitals, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses techniques of focal therapy in patients with prostate cancer.
Mark Emberton, MD, FRCS
Latest:
Dr. Emberton on the Importance of Multidisciplinary Care in Prostate Cancer
Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.
Mark H. O'Hara, MD
Latest:
Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer
Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.